Moderna, Inc. (MRNA)
| Market Cap | 10.02B |
| Revenue (ttm) | 3.18B |
| Net Income (ttm) | -3.36B |
| Shares Out | 386.74M |
| EPS (ttm) | -8.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,771,541 |
| Open | 25.71 |
| Previous Close | 25.40 |
| Day's Range | 25.42 - 26.02 |
| 52-Week Range | 23.15 - 138.07 |
| Beta | 1.86 |
| Analysts | Hold |
| Price Target | 48.13 (+85.83%) |
| Earnings Date | Jul 31, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $48.13, which is an increase of 85.83% from the latest price.
News
Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
Moderna, Inc. (NASDAQ:MRNA) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Exec...
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...
Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Moderna, Inc. (NASDAQ:MRNA) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen ...
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
What Sparked Moderna Stock Crash?
Moderna's stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the Europea...
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference Transcript
Moderna, Inc. (NASDAQ:MRNA) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jeff...
Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.
Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cuttin...
Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More
U.S. equities were mixed at midday after China hit back at the U.S. and accused Washington of violating a trade deal the two countries reached last month. President Donald Trump said on Friday that Ch...
Moderna Stock Is Rising. A New Covid Vaccine Is Coming for Some People.
Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.'s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 year...
US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for all individuals aged 65 and above, the company said on Saturday, the first endorsement since the regul...
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...
Moderna, Inc. (MRNA) Bernstein 41st Annual Strategic Decisions Conference Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Court...
HHS cancels Moderna contract for development of bird flu vaccine for humans
The Department of Health and Human Services announced this week that it had canceled its contract with Moderna to develop a bird flu mRNA vaccine for humans. In a statement, the department wrote that ...
HHS cancels Moderna bird flu deal
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
US cancels more $700 million funding for Moderna bird flu vaccine
The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the drugmak...